Functional validation focused on the top-ranked gene, IFNGR2, using in vitro glioma models.<h4>Results</h4>TRPRS robustly stratified GBM patients into high- and low-risk groups with significantly distinct overall survival across all four datasets (AUC = 0.72-0.81). The gene discussed is IFNGR2; the disease is central nervous system cancer.